License and Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended March 31,
Partner	Drug or Drug Candidate	2019		2018
Baxalta Incorporated/Takeda	ADYNOVATE®		20		10,011
Eli Lilly and Company	NKTR-358		2,500		2,354
Amgen, Inc.	Neulasta®		1,250		1,250
Other			434		112
License, collaboration and other revenue		$	4,204	$	13,727

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March 31, 2019 (in thousands):

	Three months ended March 31, 2019
Deferred revenue—December 31, 2018	$	24,636
Recognition of previously unearned revenue		(4,204	)
Deferred revenue—March 31, 2019	$	20,432